Infectious complications in children treated for hodgkin and non-hodgkin lymphomas in polish pediatric leukemia/lymphoma study group: incidence, epidemiology and etiology

Abstract The objective of this nation-wide study was to evaluate the epidemiology and profile of bacterial (BI), viral (VI), and invasive fungal disease (IFD) in patients treated for non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL) between the years 2013–2015. In the analyzed period of time, within the studied group of 328 children diagnosed and treated for lymphomas, at least one infectious complication (IC) was diagnosed i.e. 39.3% children. In these patients there were 350 episodes of IC, therein 80.6% episodes of BI, 11.1% episodes of VI, and 8.3% episodes of IFD. In both groups, NHL and HL patients, a stable level of bacterial infections, with an increase in resistance rates, and increased levels of viral and fungal infections were observed. Profile of BI does not depend on lymphoma type, with predominance of Gram-negative bacteria and higher prevalence of MDR pathogens. The overall survival of lymphoma patients with IC was comparable for different types of infections.

[1]  J. Wachowiak,et al.  Bacterial infections in pediatric hematopoietic stem cell transplantation recipients: incidence, epidemiology, and spectrum of pathogens: report of the Polish Pediatric Group for Hematopoietic Stem Cell Transplantation , 2016, Transplant infectious disease : an official journal of the Transplantation Society.

[2]  James R. Anderson,et al.  Results of the randomized Intergroup trial Inter-B-NHL Ritux 2010 for children and adolescents with high-risk B-cell non-Hodgkin lymphoma (B-NHL) and mature acute leukemia (B-AL): Evaluation of rituximab (R) efficacy in addition to standard LMB chemotherapy (CT) regimen. , 2016 .

[3]  M. Cairo,et al.  Childhood, adolescent and young adult non‐Hodgkin lymphoma: state of the science , 2016, British journal of haematology.

[4]  M. Cairo,et al.  Childhood, adolescent and young adult non‐Hodgkin lymphoma: state of the science , 2016, British journal of haematology.

[5]  J. Wachowiak,et al.  Increased risk of infections and infection-related mortality in children undergoing haematopoietic stem cell transplantation compared to conventional anticancer therapy: a multicentre nationwide study. , 2016, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[6]  K. Kelly.  Hodgkin lymphoma in children and adolescents: improving the therapeutic index. , 2015, Blood.

[7]  Miriam L. Gonzalez,et al.  Infectious complications in children with acute lymphoblastic leukemia treated in low-middle-income countries , 2015, Expert review of hematology.

[8]  Q. Hua,et al.  Severe and fatal adverse events risk associated with rituximab addition to B-cell non-Hodgkin’s lymphoma (B-NHL) chemotherapy: a meta-analysis , 2015, Journal of chemotherapy.

[9]  E. Roilides,et al.  Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation. , 2014, The Lancet. Oncology.

[10]  M. Bassetti,et al.  Multidrug-resistant bacteria: what is the threat? , 2013, Hematology. American Society of Hematology. Education Program.

[11]  D. Livermore,et al.  European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia , 2013, Haematologica.

[12]  A. Reiter.  Non-Hodgkin Lymphoma in Children and Adolescents , 2013, Klinische Pädiatrie.

[13]  M. Hacımustafaoğlu,et al.  Catheter-associated Bloodstream Infections in Pediatric Hematology-Oncology Patients , 2013, Pediatric hematology and oncology.

[14]  R. Takimoto,et al.  Epidemiology and treatment outcome of invasive fungal infections in patients with hematological malignancies , 2012, International Journal of Hematology.

[15]  A. Barone.  Antibacterial prophylaxis in neutropenic children with cancer , 2011, Pediatric reports.

[16]  G. Alangaden,et al.  Clostridium difficile infection in cancer patients and hematopoietic stem cell transplant recipients , 2010, Expert review of anti-infective therapy.

[17]  A. Attarbaschi,et al.  Vinblastine in children and adolescents with high-risk anaplastic large-cell lymphoma: results of the randomized ALCL99-vinblastine trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  L. Dupuis,et al.  Risk Factors for Infection-Related Outcomes During Induction Therapy for Childhood Acute Lymphoblastic Leukemia , 2009, The Pediatric infectious disease journal.

[19]  H. Einsele,et al.  Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia , 2009, Bone Marrow Transplantation.

[20]  H. Einsele,et al.  Management of CMV, HHV-6, HHV-7 and Kaposi-sarcoma herpesvirus (HHV-8) infections in patients with hematological malignancies and after SCT , 2008, Bone Marrow Transplantation.

[21]  Patricia Muñoz,et al.  Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  G. Escherich,et al.  Impact of reduction of therapy on infectious complications in childhood acute lymphoblastic leukemia , 2008, Pediatric blood & cancer.

[23]  G. Schwarzer,et al.  Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma. , 2007, The Cochrane database of systematic reviews.

[24]  H. Harputluoglu,et al.  Rituximab-related viral infections in lymphoma patients , 2007, Leukemia & lymphoma.

[25]  K. Schmiegelow,et al.  Infections during induction therapy of childhood acute lymphoblastic leukemia – no association to mannose‐binding lectin deficiency , 2006, European journal of haematology.

[26]  D. Kontoyiannis,et al.  Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003). , 2006, Haematologica.

[27]  E. Kimby.  Tolerability and safety of rituximab (MabThera). , 2005, Cancer treatment reviews.

[28]  Russell E. Lewis,et al.  Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. , 2005, The Journal of infectious diseases.

[29]  J. Jernigan,et al.  Impact of vancomycin resistance on mortality among patients with neutropenia and enterococcal bloodstream infection. , 2005, The Journal of infectious diseases.

[30]  C. Kramm,et al.  Infectious complications in children with acute lymphoblastic leukemia and T-cell lymphoma – a rationale for tailored supportive care , 2001, Supportive Care in Cancer.